Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.
Close
Close
Please Log In to access this content

Registered User

Please log in for full access to your permissions. Password is case sensitive.
Your session timed out.
User Name:
Password:
Automatically log me in when I return
Or Log In using:

Not Registered Yet?

Register now to get FREE access to:

Issuer Ratings.

Ratings on over 170,000 corporate, government and structured finance securities.

Events Calendar.

Information about training seminars, briefings, and teleconferences.

Watchlists.

Listings of issuers under review for rating changes.

Rating Methodologies.

Descriptive frameworks underlying Moody's ratings.

 

Actavis, Inc.

Moody's Org ID:600041994 Previous Name:WATSON PHARMACEUTICALS, INC.
You need the latest flash player to use the portfolio functionality. Please click here to download the Flash Player
To view this content, you need the latest version of the Adobe Flash Player. Download the free Flash Player Now If you are still having trouble, please click here for additional help.
Please Enter New Portfolio Name:


Please select default view:

To edit portfolio contents and set portfolio preferences (such as sharing or alerts) go to :
Moody's > Portfolios > Manage.

Cancel
Create Portfolio


Continue
 
............................................................................................................................................

To edit portfolio contents and set portfolio preferences (such as sharing or alerts) go to :
Moody's > Portfolios > Manage.

Go to this portfolio
Continue
To view this content, you need the latest version of the Adobe Flash Player. Download the free Flash Player Now If you are still having trouble, please click here for additional help.
Summary Data
Please Log In to view this content.
  • Long Term Rating
    • Date 1:
  • Outlook
  • Other Debts on Watch?:

Base BCA Indicator

Moody's uses the Baseline Credit Assessments (BCAs) to capture the mapping and translation of a Bank Financial Strength Rating (BFSR) to the Long Term rating (Aaa - C) scale. Get more information

 

Adjusted BCA Indicator

Moody's uses the Adjusted Baseline Credit Assessments (Adjusted BCA) to incorporate parental and cooperative support into the initial assessment. Get more information

  • Market Segment:Corporates
  • Industry:PHARMACEUTICALS: GENERAL & SPECIALTY
  • Peer Group:Pharmaceutical
  • Domicile:UNITED STATES
Research Ratings Family Tree Peer Group Market Signals CreditEdge Research

Issuer Research Industry Research Family Tree Research Methodology
Results 1 - 49 Of 49
Previous  Page  1 Of  1  Next
  Date Title
24 Feb 2014 Issuer Comment Actavis Deal to Buy Forest Raises Its Leverage and Integration Risk
18 Feb 2014 Credit Focus Actavis Inc.: Forest Labs Acquisition Is Riskier Than Warner Chilcott Deal
18 Feb 2014 Rating Action Moody's Affirms Actavis' Baa3; stable outlook
20 Nov 2013 Credit Focus Teva: Copaxone Threat Puts A3 Rating at Risk
08 Oct 2013 Credit Opinion Actavis, Inc.
02 Oct 2013 Announcement Correction to Text, October 1, 2013 Release: Moody's Affirms Actavis' Ratings; Upgrades Warner Chilcott's Senior Notes to Baa3
01 Oct 2013 Rating Action Moody's Affirms Actavis' Ratings; Upgrades Warner Chilcott's Senior Notes to Baa3
24 Jun 2013 Issuer Comment US Supreme Court's Pay-for-Delay Ruling Is Credit Negative for Pharma Firms
18 Jun 2013 Announcement Moody's: Supreme Court Ruling Increases Legal Risk and Uncertainty for Generic Pharma Firms
27 May 2013 Issuer Comment Actavis' All-Stock Deal for Warner Chilcott Will Decrease Leverage and Improve Cash Flow
24 May 2013 Announcement Correction to Text, May 20, 2013 Release: Moody's Affirm's Actavis' Baa3; outlook stable
23 May 2013 Credit Focus Actavis' Purchase of Warner Chilcott Is Rare Win-Win for Shareholders and Creditors
20 May 2013 Rating Action Moody's Affirm's Actavis' Baa3; outlook stable
16 May 2013 Issuer Comment Actavis' Talks to Buy Warner Chilcott Signal More Aggressive Acquisition Stance
13 May 2013 Announcement Moody's Says Actavis' Talks to Buy Warner Chilcott Signal More Aggressive Acquisition Stance
13 May 2013 Issuer Comment Actavis' Talks to Buy Warner Chilcott Signal More Aggressive Acquisition Stance
27 Sep 2012 Rating Action Moody's assigns Baa3 rating to Watson's senior notes
24 May 2012 Credit Focus Mylan Inc.: Frequently Asked Questions
25 Apr 2012 Announcement Moody's affirms Watson's Baa3 rating; outlook now stable
13 Apr 2012 Announcement Moody's Disclosures on Credit Ratings of Watson Pharmaceuticals, Inc.
25 May 2011 Announcement Moody's: No impact on Watson's Baa3 rating from Specifar deal
25 May 2011 Issuer Comment Moody's: No impact on Watson's Baa3 rating from Specifar deal
11 Mar 2011 Announcement Moody's revises Watson's rating outlook to positive from stable
13 Oct 2010 Special Comment Global Pharmaceutical Issuer Scorecard
08 Jun 2010 Rating Action Moody's raises Watson's ratings to Baa3; outlook stable
19 Nov 2009 Announcement Moody's: Outlook Negative for Global Pharmaceutical Industry The document has been translated in other languages

16 Sep 2009 Covenant Quality Assessment Watson Pharmaceuticals, Inc. - $450 million 5.000% Notes due 2014 $400 million 6.125% Notes due 2019
18 Aug 2009 Rating Action Moody's assigns Ba1 rating to Watson Pharma's new sr. notes
17 Jun 2009 Rating Action Moody's affirms Watson Pharmaceuticals at Ba1; outlook positive
01 Jun 2009 LGD Assessment Watson Pharmaceuticals, Inc.
26 May 2009 Rating Action Moody's revises outlook on Watson Pharmaceuticals to positive
13 Nov 2008 LGD Assessment Watson Pharmaceuticals, Inc.
27 Sep 2006 LGD Assessment Watson Pharmaceuticals, Inc.
21 Sep 2006 Rating Action Moody's changes ratings on 9 US pharmaceutical companies under LGD rating methodology
09 Aug 2006 Spec Grade Liquidity Assmt Watson Pharmaceuticals, Inc.
04 Aug 2006 Rating Action MOODY'S ASSIGNS Ba1 RATING TO WATSON PHARMACEUTICAL, INC.'S PROPOSED NEW BANK CREDIT FACILITY; AFFIRMS Ba1 CORPORATE FAMILY RATING; CONFIRMS SGL-1 RATING; LOWERS CONVERTIBLE NOTES RATING TO Ba2 FROM Ba1; STABLE OUTLOOK
15 Mar 2006 Rating Action MOODY'S AFFIRMS Ba1 CORPORATE FAMILY RATING OF WATSON PHARMACEUTICALS, INC. WITH STABLE RATING OUTLOOK; PLACES Ba1 SR. CONVERTIBLE DEBENTURE RATING AND SGL-1 RATING UNDER REVIEW FOR POSSIBLE DOWNGRADE
20 Jan 2006 Leveraged Credit Analysis Watson Pharmaceuticals, Inc.
16 Dec 2004 Financial Reporting Assessment Watson Pharmaceuticals, Inc.
15 Dec 2004 Rating Action MOODY'S ASSIGNS SGL-1 SPECULATIVE GRADE LIQUIDITY RATING TO WATSON PHARMACEUTICALS, INC.
24 Nov 2004 Leveraged Credit Analysis Watson Pharmaceuticals, Inc.
01 Jul 2004 Rating Action MOODY'S AFFIRMS WATSON PHARMACEUTICALS' Ba1; REVISES RATINGS OUTLOOK TO STABLE
31 Mar 2004 Financial Statement Ratios Watson Pharmaceuticals, Inc.
18 Apr 2003 Opinion Update Watson Pharmaceuticals, Inc.
24 Mar 2003 Rating Action MOODY'S RATES WATSON PHARMACEUTICALS CONVERTIBLE SR. DEBENTURES AND ITS BANK CREDIT FACILITY Ba1; OUTLOOK POSITIVE
27 Jul 2001 Rating Action MOODY'S RE-CALIBRATES ITS PREFERRED STOCK RATING SCALE TO PROMOTE CROSS-SECTOR COMPARABILITY
11 Jul 2000 Rating Action MOODY'S ASSIGNS Ba1 RATING TO WATSON PHARMACEUTICALS, INC.'S SENIOR UNSECURED CREDIT FACILITY AND CONFIRMS Ba1 RATING ON ITS SENIOR UNSECURED NOTES, WITH POSITIVE RATING OUTLOOK
30 May 2000 Rating Action MOODY'S CONFIRMS WATSON PHARMACEUTICALS, INC.'S SENIOR NOTES RATING OF Ba1, AND PLACES SCHEIN PHARMACEUTICAL, INC.'S SENIOR NOTES RATING OF Caa1 ON REVIEW FOR POSSIBLE UPGRADE
11 May 1998 Rating Action MOODY'S ASSIGNS Ba1 TO WATSON'S SR. NOTES AND SR. CREDIT FACILITY
Results 1 - 49 Of 49
Previous  Page  1 Of  1  Next

1This date does not capture any Confirmations or Watch actions. Please refer to the rating history section for additional information.

For credit ratings that are derived exclusively from an existing credit rating of a program, series, category/class of debt, support provider or primary rated entity, or that replace a previously assigned provisional rating at the same rating level, Moody’s publishes a rating announcement on that series, category/class of debt or program as a whole, on the support provider or primary rated entity, or on the provisional rating, but often does not publish a specific rating announcement on each subsequent bond or note for which the credit rating is derived from the existing credit rating. Rating announcements are usually press releases classified as Rating Actions on www.moodys.com. Please refer to the Research tab on the issuer/entity page for the rating announcement.
© 2014 Moody's Investors Service, Inc., Moody’s Analytics, Inc. and/or their affiliates and licensors. All rights reserved.
Regional Sites: